p53 gene mutations are rare in patients but common in patient-originating cell lines in multiple myeloma

References

• Levine A J, Momand J, Finlay C A. The p53 tumour suppressor gene. Nature 1991; 351: 453–6
   PubMed Web of Science ®Google Scholar
• Finlay C A, Hinds P W, Levine A J. The p53 proto-oncogene can act as a suppressor of transformation. Cell 1989; 57: 1083–93
   PubMed Web of Science ®Google Scholar
• Chen P-L, Chen Y, Bookstein R, Lee W-H. Genetic mechanisms of tumor suppression by the human p53 gene. Science 1990; 250: 1576–80
   PubMed Web of Science ®Google Scholar
• Momand J, Zambetti G P, Olson D C, George D, Levine A J. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 1992; 69: 1237–45
   PubMed Web of Science ®Google Scholar
• Oliner J D, Pietenpol J A, Thiagalingam S, Gyuris J, Kinzler K W, Vogelstein B. Oncoprotein mdm2 conceals the activation domain of tumour suppressor p53. Nature 1993; 362: 857–60
   PubMed Web of Science ®Google Scholar
• Shen Y, Shenk T. Relief of p53-mediated transcriptional repression by the adenovirus E1B 19-kDa protein or the cellular Bcl-2 protein. Proc Natl Acad Sci USA 1994; 91: 8940–4
   PubMedGoogle Scholar
• Havre P A, Yuan J, Hedrick L, Cho K R, Glazer P M. P53 inactivation by HPV16 E6 results in increased mutagenesis in human cells. Cancer Res 1995; 55: 4420–4
   PubMed Web of Science ®Google Scholar
• Stuart E T, Haffner R, Oren M, Gruss P. Loss of p53 function through PAX-mediated transcriptional repression. EMBO J 1995; 14: 5638–45
   PubMedGoogle Scholar
• Moll U M, Riou G, Levine A J. Two distinct mechanisms alter p53 in breast cancer: mutation and nuclear exclusion. Proc Natl Acad Sci USA 1992; 89: 7262–6
   PubMed Web of Science ®Google Scholar
• Hollstein M, Sidransky D, Vogelstein B, Harris C C. p53 mutations in human cancers. Science 1991; 253: 49–53
   PubMed Web of Science ®Google Scholar
• Soussi T, Caron de Fromentel C, May P. Structural aspects of the p53 protein in relation to gene evolution. Oncogene 1990; 5: 945–52
   PubMed Web of Science ®Google Scholar
• Lowe S W, Bodis S, McClatchey A, Remington L, Ruley E H, Fisher D E. p53 status and the efficacy of cancer therapy in vivo. Science 1994; 266: 807–10
   PubMed Web of Science ®Google Scholar
• Imamura J, Miyoshi I, Koeffler H P. p53 in hematological malignancies. Blood 1994; 84: 2412–21
   PubMed Web of Science ®Google Scholar
• Newcomb E W. P53 gene mutations in lymphoid diseases and their possible relevance to drug resistance. Leukemia Lymphoma 1995; 17: 211–21
   PubMed Web of Science ®Google Scholar
• Reich N C, Levine A J. Growth regulation of a cellular tumour antigen, p53, in nontransformed cells. Nature 1984; 308: 199–201
   PubMed Web of Science ®Google Scholar
• Metcalf R A, Welsh J A, Bennett W P, Seddon M B, Lehman T A, Pelin K. P53 and kirsten-ras mutations in human mesothelioma cell lines. Cancer Res 1992; 52: 2610–15
   PubMedGoogle Scholar
• Kennedy S M, MacGeogh C, Jaffe R, Spurr N K. Overexpression of the oncoprotein p. 53 in primary hepatic tumors of childhood does not correlate with gene mutations. Hum Pathol 1994; 25: 438–42
   PubMed Web of Science ®Google Scholar
• Greco C, Gandolfo G M, Mattei F, Gradilone A, Alvino S, Pastore L L. Detection of c-myb genetic alterations and mutant p53 serum protein in patients with benign and malignant colon lesions. Anticancer Res 1994; 14: 1433–40
   PubMed Web of Science ®Google Scholar
• Luo J-C, Zehab R, Anttila R, Ridanpää M, Husgafvel-Pursiainen K, Vainio H. Detection of serum p53 protein in lung cancer patients. J Occup Med 1994; 36: 155–60
   PubMedGoogle Scholar
• Braun A, Straif K, Konietzko N, Wiesner B, Loeffler S, Presek P. Detection of oncogene and tumor suppressor gene products in serum of former uranium miners for secondary prevention of radon-induced lung cancer. Clin Chem 1995; 41: 1913–15
   Google Scholar
• Partanen R, Koskinen H, Oksa P, Hemminki K, Carney W, Smith S. Serum oncoproteins in asbestosis patients. Clin Chem 1995; 41: 1844–7
   PubMed Web of Science ®Google Scholar
• Pulkki K, Ollikainen H, Rajamaki A, Pelliniemi T-T. Serum p53 oncoprotein and p53 antibodies as prognostic factors in multiple myeloma (MM). Blood 1995; 86: 64a, Suppl
   Google Scholar
• Durie B GM, Salmon S E. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 1975; 36: 842–54
   PubMed Web of Science ®Google Scholar
• Koskela K, Pelliniemi T-T, Remes K, Savino R, Ciliberto G, Pulkki K. Establishment of three new myeloma cell lines from bone marrow plasma cells: response to interleukin-6 and interleukin-6-antagonist. Vth international workshop on multiple myeloma. La Baule, France 10–13 September, 1995, Meeting Abstract 3.83
   Google Scholar
• Puranen M, Saarikoski S, Syrjänen K, Syrjänen S. Polymerase chain reaction amplification of human papillomavirus DNA from archival Papanicolau-stained cervical smears. Acta Cytol 1996; 40: 391–5
   PubMedGoogle Scholar
• Miller S A, Dykes D D, Polesky H F. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988; 16: 1215
   PubMed Web of Science ®Google Scholar
• Buchman V L, Chumakov P M, Ninkina N N, Samarine OP., Georgiev G P. A variation in the structure of the protein-coding region of the human p53 gene. Gene 1988; 70: 245–252
   PubMed Web of Science ®Google Scholar
• Kurvinen K, Hietanen S, Syrjänen K, Syrjänen S. Rapid and effective detection of mutations in the p53 gene using nonradioactive single-strand conformation polymorphism (SSCP) technique applied on PhastSystem™. J Virol Methods 1995; 51: 43–54
   PubMedGoogle Scholar
• Crook T, Wrede D, Vousden K H. p53 point mutation in HPV negative human cervical carcinoma cell lines. Oncogene 1991; 6: 873–5
   PubMed Web of Science ®Google Scholar
• Lehman T A, Modali R, Boukamp P, Stanek J, Bennett W P, Welsh J A. p53 mutations in human immortalized epithelial cell lines. Carcinogenesis 1993; 14: 833–9
   PubMed Web of Science ®Google Scholar
• Bataille R, Boccadoro M, Klein B, Durie B, Pileri A. C-reactive protein and (5–2 microglobulin produce a simple and powerful myeloma staging system. Blood 1992; 80: 733–7
   PubMed Web of Science ®Google Scholar
• Pelliniemi T-T, Irjala K, Mattila K, Pulkki K, Rajamaki A, Tienhaara A. Immunoreactive interleukin-6 and acute phase proteins as prognostic factors in multiple myeloma. Blood 1995; 85: 765–71
   PubMed Web of Science ®Google Scholar
• Orita M, Iwahana H, Kanazawa H, Hayashi K, Sekiya T. Detection of polymorphism of human DNA by gel electrophoresis as single-strand conformation polymorphisms. Proc Natl Acad Sci USA 1989; 86: 2766–70
   PubMed Web of Science ®Google Scholar
• Preudhomme C, Facon T, Zandecki M, Vanrumbeke M, Lay J L, Nataf E. Rare occurrence of P53 gene mutations in multiple myeloma. Br J Haematol 1992; 81: 440–3
   PubMed Web of Science ®Google Scholar
• Portier M, Molès J-P, Mazars G-R, Jeanteur P, Bataille R, Klein B. p53 and ras gene mutations in multiple myeloma. Oncogene 1992; 7: 2539–43
   PubMed Web of Science ®Google Scholar
• Neri A, Baldini L, Trecca D, Cro L, Polli E, Maiolo A T. p53 gene mutations in multiple myeloma are associated with advanced forms of malignancy. Blood 1993; 81: 128–35
   PubMed Web of Science ®Google Scholar
• Corradini P, Inghirami G, Astolfi M, Ladetto M, Voena C, Ballerini P. Inactivation of tumor suppressor genes p53 and Rb1. in plasma cell dyscrasias. Leukemia 1994; 8: 758–67
   PubMed Web of Science ®Google Scholar
• Yasuga Y, Hirosawa S, Yamamoto K, Tomiyama J, Nagata K, Aokia N. N-ras and p53 mutations are very rare events in multiple mveloma. Int J Hematol 1995; 62: 91–7
   PubMed Web of Science ®Google Scholar
• Mazars G-R, Portier M, Zhang X-G, Jourdan M, Bataille R, Theillet C. Mutations of the p53 gene in human myeloma cell lines. Oncogene 1992; 7: 1015–18
   PubMed Web of Science ®Google Scholar
• Hayashi K. PCR-SSCP: a method for detection of mutations. GATA, 9: 73–9
   PubMedGoogle Scholar